Chiu, Ami
Hartz, Sarah
Smock, Nina
Chen, Jingling
Qazi, Amaan
Onyeador, Jeffrey
Ramsey, Alex T.
Bierut, Laura J.
Chen, Li-Shiun http://orcid.org/0000-0001-6762-5054
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA038076, R21DA044744, K12DA041449, R01DA036583)
National Cancer Institute (P01CA089392, P30CA091842)
National Institute on Alcohol Abuse and Alcoholism (R21AA024888)
National Center for Advancing Translational Sciences (UL1TR002345)
Article History
Received: 23 July 2018
Accepted: 18 October 2018
First Online: 29 October 2018
Compliance with Ethical Standards
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: LJB is listed as an inventor on Issued U.S. Patent 8,080,371 “Markers for Addiction” covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction, and served as a consultant for the pharmaceutical company Pfizer in 2008. The remaining authors declare no conflict of interest.